

# Hans Salwender

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1342529/publications.pdf>

Version: 2024-02-01

46  
papers

4,741  
citations

279798

23  
h-index

233421

45  
g-index

46  
all docs

46  
docs citations

46  
times ranked

4912  
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	27.0	1,210
2	Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2946-2955.	1.6	735
3	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
4	Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. <i>Blood</i> , 2012, 119, 940-948.	1.4	327
5	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. <i>Blood</i> , 2019, 133, 840-851.	1.4	228
6	Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A. <i>Journal of Clinical Oncology</i> , 2010, 28, 4642-4648.	1.6	205
7	Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007, 138, 330-337.	2.5	156
8	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	1.6	115
9	Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. <i>Haematologica</i> , 2014, 99, 148-154.	3.5	113
10	Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). <i>Annals of Hematology</i> , 2014, 93, 1083-1095.	1.8	86
11	Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patientsâ€™ a double-blind, randomised, prospective, controlled trial. <i>Supportive Care in Cancer</i> , 2005, 13, 993-1000.	2.2	76
12	Central venous catheter-related infections in hematology and oncology. <i>Annals of Hematology</i> , 2008, 87, 863-876.	1.8	71
13	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. <i>Haematologica</i> , 2015, 100, 964-969.	3.5	62
14	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. <i>Annals of Hematology</i> , 2016, 95, 1931-1942.	1.8	61
15	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.4	61
16	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , 2013, 122, 767-767.	1.4	56
17	Central venous catheter (CVC)-related infections in neutropenic patients. <i>Annals of Hematology</i> , 2003, 82, S149-S157.	1.8	55
18	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. <i>Leukemia</i> , 2022, 36, 885-888.	7.2	38

#	ARTICLE	IF	CITATIONS
19	Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. <i>Haematologica</i> , 2016, 101, e116-e119.	3.5	37
20	Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLAPsE. <i>Leukemia</i> , 2021, 35, 1134-1144.	7.2	36
21	Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: the DSMM XI trial. <i>British Journal of Haematology</i> , 2017, 179, 586-597.	2.5	30
22	Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. <i>Haematologica</i> , 2016, 101, 1398-1406.	3.5	28
23	Survival of elderly patients with multiple myeloma—Effect of upfront autologous stem cell transplantation. <i>European Journal of Cancer</i> , 2016, 62, 1-8.	2.8	27
24	Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2018, 2, 1-9.	5.2	25
25	Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. <i>BMC Cancer</i> , 2019, 19, 504.	2.6	25
26	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. <i>Haematologica</i> , 2016, 101, 839-845.	3.5	22
27	Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2387-2396.	1.8	21
28	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.	2.5	16
29	Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. <i>Blood</i> , 2011, 117, 2121-2128.	1.4	15
30	Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. <i>European Journal of Haematology</i> , 2017, 99, 42-50.	2.2	15
31	Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. <i>Haematologica</i> , 2016, 101, e485-e487.	3.5	14
32	Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. <i>Haematologica</i> , 2017, 102, 1432-1438.	3.5	14
33	Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. <i>BMC Medical Genomics</i> , 2015, 8, 85.	1.5	7
34	Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 65.	17.0	7
35	Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 71.	6.2	7
36	Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. <i>Oncotarget</i> , 2017, 8, 84847-84862.	1.8	7

#	ARTICLE	IF	CITATIONS
37	Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials. <i>European Journal of Haematology</i> , 2019, 103, 255-267.	2.2	6
38	Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM. <i>Cancers</i> , 2021, 13, 1322.	3.7	6
39	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLapsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. <i>BMC Cancer</i> , 2016, 16, 290.	2.6	5
40	Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects. <i>Leukemia and Lymphoma</i> , 2020, 61, 2365-2374.	1.3	4
41	Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. <i>Leukemia</i> , 2021, 35, 3007-3011.	7.2	4
42	Convenient Access to Expert-Reviewed Health Information via an Alexa Voice Assistant Skill for Patients With Multiple Myeloma: Development Study. <i>JMIR Cancer</i> , 2022, 8, e35500.	2.4	4
43	Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 529-542.	2.2	3
44	Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. <i>Cancers</i> , 2021, 13, 4856.	3.7	3
45	GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy. <i>Blood</i> , 2013, 122, 3369-3369.	1.4	3
46	Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 368-376.	1.3	0